In the golden season of September, the autumn breeze brings us cool. Zhuhai Topchain Pharmaceutical Co., Ltd. ("Topchain Pharma" for short) took part in a lecture tour on pharmaceutical preparation technologies to top 100 pharmaceutical enterprises: WuXi AppTec and Yangtze River Pharmaceutical Group hosted by China Pharmaceutical Excipients Council (CPEC) and organized by international pharmaceutical preparations network PHEXCOM. Topchain Pharma shared its studies on innovative microcrystalline cellulose (MCC) products and their applications with nearly 100 participants present.
Firstly, the keynote speaker introduced the profile of the company to the participants. Affiliated to Shenzhen Youpuhui Pharmaceutical Co., Ltd., Topchain Pharma is the only manufacturer that produces pharmaceutical-grade and food-grade MCC products in Guangdong. Based on the thinking of building a pharmaceutical factory, the company has constructed manufacturing workshops that meet the GMP requirements and obtained the ISO9001 Quality Management System Certification. Its MCC Series products have been granted the FDA's DMF No. 032755, and some conventional model products have been given the CDE's associated registration number F20180000805, which will be activated soon.
Then, the speaker gave an introduction to the company's innovative MCC products such as TONCELLUS®TL/TF/TLF/TCD Series products prepared through physical modification, further improving the scope of MCC application. Topchain Pharma has also developed the TONCELLUS®TP Core Pellet Series manufactured from 100% MCC with high sphericity and zero friability but without addition of any other substance. In the series, Model TP102 has broken the monopoly of imported manufacturers on MCC core pellets with small particle sizes. In addition, the customized co-processed MCC excipient TMF955 can meet the customers’ development needs of orally disintegrating tablets. Immediately afterwards, the excellent performance of Topchain Pharma's innovative products was demonstrated through experiments.